ProCE Banner Activity

Injectable Long-Acting ART: Optimizing Evidence-Based Candidate Selection

Clinical Thought
Here’s my take on incorporating the available evidence to select the right patients for HIV treatment with long-acting injectable cabotegravir plus rilpivirine.

Released: July 25, 2022

Expiration: July 24, 2023

No longer available for credit.

Share

Faculty

Cristina Mussini

Cristina Mussini, MD

Full Professor of Infectious Diseases
Chief of the Clinic of Infectious Diseases, University Hospital of Modena
University of Modena and Reggio Emilia
Modena, Italy

Provided by

Provided by Clinical Care Options, LLC.
ProCE Banner

Supporters

Supported by an educational grant from

ViiV Healthcare

Faculty Disclosure

Primary Author

Cristina Mussini, MD

Full Professor of Infectious Diseases
Chief of the Clinic of Infectious Diseases, University Hospital of Modena
University of Modena and Reggio Emilia
Modena, Italy

Cristina Mussini, MD: consultant: AbbVie, Angelini, Gilead Sciences, Janssen, MSD, Pfizer, ViiV Healthcare; researcher: Gilead Sciences, Janssen, MSD, ViiV Healthcare.